Adamis Pharmaceuticals Corp. (ADMP)

0.85
NASDAQ : Health Technology
Prev Close 0.85
Day Low/High 0.84 / 0.87
52 Wk Low/High 0.70 / 4.25
Avg Volume 617.30K
Exchange NASDAQ
Shares Outstanding 61.44M
Market Cap 52.28M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Adamis Pharmaceuticals Provides Launch And Marketing Update For SYMJEPI

Adamis Pharmaceuticals Provides Launch And Marketing Update For SYMJEPI

SAN DIEGO, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided a progress report and marketing update on the U.

Adamis Pharmaceuticals Announces Appointment Of New Members To Its Board Of Directors

Adamis Pharmaceuticals Announces Appointment Of New Members To Its Board Of Directors

SAN DIEGO, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the appointment of Howard C.

Adamis Pharmaceuticals Strengthens Patent Portfolio For Its U.S. Compounding Subsidiary

Adamis Pharmaceuticals Strengthens Patent Portfolio For Its U.S. Compounding Subsidiary

SAN DIEGO, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application (U.

Adamis Pharmaceuticals Announces Second Quarter 2019 Financial Results And Business Update

Adamis Pharmaceuticals Announces Second Quarter 2019 Financial Results And Business Update

SAN DIEGO, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the second quarter ended June 30, 2019 and provided a business update.

Adamis Pharmaceuticals Schedules Second Quarter 2019 Earnings Conference Call And Business Update

Adamis Pharmaceuticals Schedules Second Quarter 2019 Earnings Conference Call And Business Update

SAN DIEGO, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) ("Adamis"), a specialty biopharmaceutical company primarily focused on developing and commercializing products in the therapeutic areas of allergy, respiratory...

Adamis Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock And Warrants

Adamis Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock And Warrants

SAN DIEGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including respiratory disease, allergy...

Adamis Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Warrants

Adamis Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Warrants

SAN DIEGO, July 31, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including respiratory disease, allergy...

Interesting ADMP Call Options For March 2020

Interesting ADMP Call Options For March 2020

Investors in Adamis Pharmaceuticals Corp. saw new options become available this week, for the March 2020 expiration.

Adamis Pharmaceuticals Provides Update On Litigation With Belcher Pharmaceuticals

Adamis Pharmaceuticals Provides Update On Litigation With Belcher Pharmaceuticals

SAN DIEGO, July 24, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) ("Adamis") announced today that Adamis and Belcher Pharmaceuticals, LLC ("Belcher") agreed to settle all previously filed litigation between the parties,...

Adamis Pharmaceuticals Provides Update On Litigation With Kaléo Inc.

Adamis Pharmaceuticals Provides Update On Litigation With Kaléo Inc.

SAN DIEGO, July 18, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) ("Adamis") announced today that Adamis and kaléo Inc.

Adamis Pharmaceuticals Provides Update On U.S. Retail Launch Of SYMJEPI

Adamis Pharmaceuticals Provides Update On U.S. Retail Launch Of SYMJEPI

SAN DIEGO, July 09, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) provided an update that Sandoz Inc.

Interesting ADMP Call Options For December 20th

Interesting ADMP Call Options For December 20th

Investors in Adamis Pharmaceuticals Corp. saw new options become available this week, for the December 20th expiration.

Adamis Pharmaceuticals Announces FDA Acceptance For Review Of The New Drug Application Of Its Higher Dose Naloxone Injection Product Candidate

Adamis Pharmaceuticals Announces FDA Acceptance For Review Of The New Drug Application Of Its Higher Dose Naloxone Injection Product Candidate

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S.

These 2 Biotech Stocks Seem Significantly Undervalued

These 2 Biotech Stocks Seem Significantly Undervalued

I would add to them on any significant dips in the market.

First Week Of ADMP June 2019 Options Trading

First Week Of ADMP June 2019 Options Trading

Investors in Adamis Pharmaceuticals Corp. saw new options become available this week, for the June 2019 expiration.

Why Investors Should Favor Smaller Biotech Companies

Why Investors Should Favor Smaller Biotech Companies

Small and mid-cap biotech firms are driving innovation in the sector. Experts explain why investors should take notice.

Biotech Stocks Getting Their Due Respect

Biotech Stocks Getting Their Due Respect

Here are two I think will bounce back before the end of the year.

5 Big Biotech Stories to Watch

5 Big Biotech Stories to Watch

The biotech and pharmaceutical industries have had some big news in recent weeks. Here's what you should know to stay up-to-date.

2 Small Biotechs I Like in the Second Half

2 Small Biotechs I Like in the Second Half

Adamis Pharmaceuticals and Pieris Pharmaceuticals are names to watch.

Adamis Pharma Shares Soar on Deal With Novartis for Epipen Competitor

Adamis Pharma Shares Soar on Deal With Novartis for Epipen Competitor

Adamis' device to treat allergic reactions should compete effectively with Mylan's popular EpiPen, according to an analyst.

First Week Of ADMP August 17th Options Trading

First Week Of ADMP August 17th Options Trading

Investors in Adamis Pharmaceuticals Corp. saw new options begin trading this week, for the August 17th expiration.

TheStreet Quant Rating: D (Sell)